A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer

Cancer Letters

Volumn 343, Issue 1, 2014, Pages 33-41

  Jobard, Elodie ^a,b   Pontoizeau, Clément ^a   Blaise, Benjamin J ^a   Bachelot, Thomas ^b   Elena Herrmann, Bénédicte ^a   Trédan, Olivier ^b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Breast cancer; Metabolomics; Metabonomics; Metastatic; NMR; Serum

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; BETAINE; GLUTAMIC ACID; GLYCEROL; GLYCOPROTEIN; HISTIDINE; MANNOSE; PHENYLALANINE; PYRUVIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER CLASSIFICATION; CLINICAL ARTICLE; DISEASE MARKER; DISEASE SEVERITY; FATTY ACID OXIDATION; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; METABOLOMICS; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84890858348     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.011     Document Type: Article

References (61)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, eds., Globocan 2008 v2.0, Cancer incidence and mortality worldwide: IARC cancer base no. 10, Lyon, France: International Agency for Research on, Cancer, 2008.
2. Vineis P.P., Perera F.F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidem. Biomar. 2007, 16:1954-1965.
3. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
4. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24:3726-3734.
5. Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer I 2006, 98:1183-1192.
6. Dubsky P., Filipits M., Jakesz R., Rudas M., Singer C.F., Greil R., et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann. Oncol. 2012, 640-647.
7. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
8. Henneges C., Bullinger D., Fux R., Friese N., Seeger H., Neubauer H., et al. Prediction of breast cancer by profiling of urinary RNA metabolites using support vector machine-based feature selection. BMC Cancer 2009, 9:104.
9. Keun H.C., Sidhu J., Pchejetski D., Lewis J.S., Marconell H., Patterson M., et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin. Cancer Res. 2009, 15:6716-6723.
10. Nicholson J., Lindon J., Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
11. Fiehn O. Metabolomics - the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48:155-171.
12. Zhang S., Gowda G.A.N., Ye T., Raftery D. Advances in NMR-based biofluid analysis and metabolite profiling. Analyst 2010, 135:1490-1498.
13. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4:551-561.
14. Motta A., Paris D., Melck D., de Laurentiis G., Maniscalco M., Sofia M., et al. Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects. Eur. Respir. J. 2012, 39:498-500.
15. Montuschi P., Paris D., Melck D., Lucidi V., Ciabattoni G., Raia V., et al. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax 2012, 67:222-228.
16. Robertson D. Metabonomics in toxicology: a review. Toxicol. Sci. 2005, 85:809-822.
17. Raamsdonk L., Teusink B., Broadhurst D., Zhang N., Hayes A., Walsh M., et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 2001, 19:45-50.
18. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
19. Odunsi K., Wollman R.M., Ambrosone C.B., Hutson A., McCann S.E., Tammela J., et al. Detection of epithelial ovarian cancer using H-1-NMR-based metabonomics. Int. J. Cancer 2004, 113:782-788.
20. Cheng L.L., Chang I.W., Smith B.L., Gonzalez R.G. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J. Magn. Reson. 1998, 135:194-202.
21. Sitter B., Bathen T.F., Tessem M.-B., Gribbestad I.S. High-resolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer. Prog. Nucl. Mag. Res. Sp. 2009, 54:239-254.
22. Sitter B., Lundgren S., Bathen T.F., Halgunset J., Fjosne H.E., Gribbestad I.S. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006, 19:30-40.
23. Bathen T.F., Jensen L.R., Sitter B., Fjoesne H.E., Halgunset J., Axelson D.E., et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res. Treat. 2006, 104:181-189.
24. Giskeodegard G.F., Grinde M.T., Sitter B., Axelson D.E., Lundgren S., Fjosne H.E., et al. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J. Proteome Res. 2010, 9:972-979.
25. Borgan E., Sitter B., Johnsen H., Lundgren S., Bathen T.F., et al. Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer 2010, 10:628.
26. Nam H., Chung B.C., Kim Y., Lee K., Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 2009, 25:3151-3157.
27. 1HH-NMR metabonomics analysis of sera differentiates between mammary tumor-bearing mice and healthy controls. Metabolomics 2005, 1:269-278.
28. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 2010, 16:5835-5841.
29. Asiago V.M., Alvarado L.Z., Shanaiah N., Gowda G.A.N., Owusu-Sarfo K., Ballas R.A., et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70:8309-8318.
30. Oakman C., Tenori L., Claudino W.M., Cappadona S., Nepi S., Battaglia A., et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 2011, 22:1295-1301.
31. Beckonert O., Keun H.C., Ebbels T.M.D., Bundy J.G., Holmes E., Lindon J.C., et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2:2692-2703.
32. Savorani F., Tomasi G., Engelsen S.B. Icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J. Magn. Res. 2010, 202:190-202.
33. Trygg J., Wold S. Orthogonal projections to latent structures (O-PLS). J. Chemometr. 2002, 16:119-128.
34. Eriksson L., Trygg J., Wold S. CV-ANOVA for significance testing of PLS and OPLS (R) models. J. Chemometr. 2008, 22:594-600.
35. Blaise B.J., Shintu L., Elena B., Emsley L., Dumas M.-E., Toulhoat P. Statistical recoupling prior to significance testing in nuclear magnetic resonance based metabonomics. Anal. Chem. 2009, 81:6242-6251.
36. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. B. 1995, 57:289-300.
37. Cloarec O., Dumas M., Craig A., Barton R., Trygg J., Hudson J., et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic H-1 NMR data sets. Anal. Chem. 2005, 77:1282-1289.
38. Cui Q., Lewis I.A., Hegeman A.D., Anderson M.E., Li J., Schulte C.F., et al. Metabolite identification via the madison metabolomics consortium database. Nat. Biotechnol. 2008, 26:162-164.
39. Wishart D.S., Knox C., Guo A.C., Eisner R., Young N., Gautam B., et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009, 37:D603-D610.
40. Ulrich E.L., Akutsu H., Doreleijers J.F., Harano Y., Ioannidis Y.E., Lin J., et al. BioMagResBank. Nucleic Acids Res. 2008, 36:D402-D408.
41. Bollard M., Stanley E., Lindon J., Nicholson J., Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 2005, 18:143-162.
42. Whitehead T., Kieber-Emmons T. Applying in vitro NMR spectroscopy and H-1 NMR metabonomics to breast cancer characterization and detection. Prog. Nucl. Mag. Res. Sp. 2005, 47:165-174.
43. Oakman C., Tenori L., Biganzoli L., Santarpia L., Cappadona S., Luchinat C., et al. Uncovering the metabolomic fingerprint of breast cancer. Int. J. Biochem. Cell B 2010, 1-11.
44. Chan E.C.Y., Koh P.K., Mal M., Cheah P.Y., Eu K.W., et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 2009, 8:352-361.
45. 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009, 100:782-785.
46. Neurauter G., Grahmann A.V., Klieber M., Zeimet A., Ledochowski M., Sperner-Unterweger B., et al. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett. 2008, 272:141-147.
47. Qiu Y., Cai G., Su M., Chen T., Zheng X., Xu Y., et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J. Proteome Res. 2009, 8:4844-4850.
48. Lai H.-S., Lee J.-C., Lee P.-H., Wang S.-T., Chen W.-J. Plasma free amino acid profile in cancer patients. Semin. Cancer Biol. 2005, 15:267-276.
49. Miyagi Y., Higashiyama M., Gochi A., Akaike M., Ishikawa T., Miura T., et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS ONE 2011, 6:e24143.
50. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
51. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
52. Wang J.-B.J., Erickson J.W.J., Fuji R.R., Ramachandran S.S., Gao P.P., Dinavahi R.R., et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010, 18:207-219.
53. Budczies J., Denkert C., Müller B.M., Brockmöller S.F., Klauschen F., Györffy B., et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue: a GC-TOFMS based metabolomics study. BMC Genom. 2012, 13:1-11.
54. Jerby L., Wolf L., Denkert C., Stein G.Y., Hilvo M., Oresic M., et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 2012, 72:5712-5720.
55. Qiu Y., Cai G., Su M., Chen T., Liu Y., Xu Y., et al. Urinary metabonomic study on colorectal cancer. J. Proteome Res. 2010, 9:1627-1634.
56. Garcia-Caballero M., Neugebauer E., Campos R., Numez de Castro I., Vara-Thorbeck C., et al. Increased histidine decarboxylase (HDC) activity in human colorectal cancer: results of a study on ten patients. Agents Actions 1988, 23:1-4.
57. Xu X., Gammon M.D., Zeisel S.H., Bradshaw P.T., Wetmur J.G., Teitelbaum S.L., et al. High intakes of choline and betaine reduce breast cancer mortality in a population-based study. FASEB J. 2009, 23:4022-4028.
58. De Leoz M.L.A., Young L.J.T., An H.J., Kronewitter S.R., Kim J., Miyamoto S., et al. High-mannose glycans are elevated during breast cancer progression. Mol. Cell. Proteomics 2011, 10:1-9.
59. Berg J.M., Tymoczko J.L., Stryer L. Fatty acid metabolism. Biochemistry 2002, 617-732. Freeman WH, New York. fifth ed. W.H. Freeman (Ed.).
60. Bonuccelli G., Tsirigos A., Whitaker-Menezes D., Pavlides S., Pestell R.G., Chiavarina B., et al. Ketones and lactate "fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.
61. Bell J.D., Brown J.C., Nicholson J.K., Sadler P.J. Assignment of resonances for "acute-phase" glycoproteins in high resolution proton NMR spectra of human blood plasma. FEBS Lett. 1987, 215:311-315.